1,098 reports of this reaction
5.5% of all METHOXY POLYETHYLENE GLYCOL EPOETIN BETA reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, manufactured by Vifor (International) Inc.. There are 1,098 FDA adverse event reports linking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA to DYSPNOEA. This represents approximately 5.5% of all 19,964 adverse event reports for this drug.
Patients taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among METHOXY POLYETHYLENE GLYCOL EPOETIN BETA users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,098 FDA reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 5.5% of all adverse event reports for METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking METHOXY POLYETHYLENE GLYCOL EPOETIN BETA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.